Pertuzumab - Genentech/Roche
Alternative Names: Anti-2C4 monoclonal antibody; Omnitarg; Perjeta; R-1273; RG-1273; rhuMab-2C4; rhuMAb2C4; Ro 436-8451/F01; RO-4368451-F01; RO4368451Latest Information Update: 14 Feb 2024
At a glance
- Originator Genentech; Roche
- Developer Chugai Pharmaceutical; Dana-Farber Cancer Institute; FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO; Genentech; Japan Breast Cancer Research Group; Medica Scientia Innovation Research; Roche; West German Study Group
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Dimerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Breast cancer
- Phase III Ovarian cancer
- Phase II Brain metastases; Colorectal cancer
- Phase I HER2 positive breast cancer
- Discontinued Gastric cancer; Non-small cell lung cancer; Prostate cancer
Most Recent Events
- 05 Dec 2023 Updated efficacy data from the phase III APHINITY trial in Breast cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)
- 13 Nov 2023 Phase-I clinical trials in HER2-positive-breast-cancer (Early-stage disease, Metastatic disease, Combination therapy) (IV), prior to November 2023 (Genentech communications, November 2023)
- 01 Nov 2023 MedSIR completes a phase-II trials in Breast cancer (Neoadjuvant therapy) in Belgium, France, Germany, Italy, Portugal, Spain, United Kingdom (IV) (NCT03161353) (EudraCT2016-002676-27)